These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 14612937

  • 1. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma.
    Kaicker S, McCrudden KW, Beck L, New T, Huang J, Frischer JS, Serur A, Kadenhe-Chiweshe A, Yokoi A, Kandel JJ, Yamashiro DJ.
    Int J Oncol; 2003 Dec; 23(6):1651-5. PubMed ID: 14612937
    [Abstract] [Full Text] [Related]

  • 2. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 3. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
    Ng SS, MacPherson GR, Gütschow M, Eger K, Figg WD.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4192-7. PubMed ID: 15217957
    [Abstract] [Full Text] [Related]

  • 4. [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
    Zhai Y, Lu ZJ.
    Ai Zheng; 2003 Dec 15; 22(12):1301-6. PubMed ID: 14693056
    [Abstract] [Full Text] [Related]

  • 5. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
    McCrudden KW, Hopkins B, Frischer J, Novikov A, Huang J, Kadenhe A, New T, Yokoi A, Yamashiro DJ, Kandel JJ, Middlesworth W.
    J Pediatr Surg; 2003 Mar 15; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
    [Abstract] [Full Text] [Related]

  • 6. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.
    Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA.
    Cancer Chemother Pharmacol; 2004 Feb 15; 53(2):133-40. PubMed ID: 14593497
    [Abstract] [Full Text] [Related]

  • 7. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
    Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.
    Int J Oncol; 2004 Sep 15; 25(3):549-53. PubMed ID: 15289855
    [Abstract] [Full Text] [Related]

  • 8. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor.
    Kim E, Moore J, Huang J, Soffer S, Manley CA, O'Toole K, Middlesworth W, Stolar CJ, Kandel JJ, Yamashiro DJ.
    J Pediatr Surg; 2001 Feb 15; 36(2):287-90. PubMed ID: 11172417
    [Abstract] [Full Text] [Related]

  • 9. Effect of thalidomide on colorectal cancer liver metastases in CBA mice.
    Daruwalla J, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V, Christophi C.
    J Surg Oncol; 2005 Aug 01; 91(2):134-40. PubMed ID: 16028287
    [Abstract] [Full Text] [Related]

  • 10. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
    Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL.
    Cancer Res; 2007 Feb 15; 67(4):1716-24. PubMed ID: 17308113
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-angiogenic effects and regression of localized murine AML produced by anti-VEGF and anti-Flk-1 antibodies.
    Reichert F, Barak V, Tarshis M, Prindull G, Tarshis E, Ben-Ishay Z.
    Eur J Haematol; 2005 Jul 15; 75(1):41-6. PubMed ID: 15946309
    [Abstract] [Full Text] [Related]

  • 13. Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice.
    Zhang ZL, Liu ZS, Sun Q.
    Chin Med J (Engl); 2005 Oct 20; 118(20):1688-94. PubMed ID: 16313753
    [Abstract] [Full Text] [Related]

  • 14. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.
    Du GJ, Lin HH, Xu QT, Wang MW.
    Vascul Pharmacol; 2005 Aug 20; 43(2):112-9. PubMed ID: 15982930
    [Abstract] [Full Text] [Related]

  • 15. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.
    Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M, Ribatti D.
    Oncogene; 2005 Oct 13; 24(45):6785-95. PubMed ID: 16007159
    [Abstract] [Full Text] [Related]

  • 16. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X, Yu Y, Zhang ZY.
    Chin Med J (Engl); 2008 Nov 20; 121(22):2324-30. PubMed ID: 19080341
    [Abstract] [Full Text] [Related]

  • 17. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 18. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
    Fukasawa M, Korc M.
    Clin Cancer Res; 2004 May 15; 10(10):3327-32. PubMed ID: 15161686
    [Abstract] [Full Text] [Related]

  • 19. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
    Straight AM, Oakley K, Moores R, Bauer AJ, Patel A, Tuttle RM, Jimeno J, Francis GL.
    Cancer Chemother Pharmacol; 2006 Jan 15; 57(1):7-14. PubMed ID: 16001179
    [Abstract] [Full Text] [Related]

  • 20. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor.
    Soffer SZ, Kim E, Moore JT, Huang J, Yokoi A, Manley C, O'Toole K, Middlesworth W, Stolar C, Yamashiro D, Kandel J.
    J Pediatr Surg; 2001 Dec 15; 36(12):1781-4. PubMed ID: 11733906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.